Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Podcast | Sexual health in older age

Dr Holly Thomas helps us unpack the needlessly taboo subject of sex and sexual health in women of older age.

Listen now
ADVANCED SEARCH
Log in
Top
Inflammopharmacology

05-03-2025 | Osteoporosis | Original Article

Therapeutic efficacy of zoledronic acid combined with calcium and calcitriol in the treatment of senile osteoporosis in elderly patients

Authors: Yi Zhang, Yuan Tian, Xiaojun Chen

Published in: Inflammopharmacology

Login to get access

Abstract

Objective

To investigate the effectiveness and safety of combining zoledronic acid with calcium supplements and calcitriol in treating primary osteoporosis in elderly patients.

Methods

Seventy-eight elderly patients with primary osteoporosis were recruited. They were randomly assigned in a 1:1 ratio to either the CC group (calcium carbonate D3 tablets + calcitriol soft capsules) or the CCZ group (calcium carbonate D3 tablets + calcitriol soft capsules + zoledronic acid injection). The treatment duration was 1 year. Bone mineral density (BMD), bone metabolism markers, quality of life (QoL), clinical efficacy, and incidence of adverse reactions (ARs) were assessed.

Results

CCZ group showed increased BMD in the lumbar spine (L1~L4 segments), femoral neck, and hip after treatment relative to CC group. Serum levels of bone-specific alkaline phosphatase, cross-linked type 1 collagen C-terminal peptide, and N-terminal propeptide of type 1 procollagen decreased, while osteocalcin levels increased. The QoL Questionnaire of the European Foundation for Osteoporosis scores decreased (P < 0.05 for all comparisons). The clinical effective rates were 76.93% in the CC group and 92.31% in the CCZ group, with AR rates of 23.08% and 12.82%, respectively (P < 0.05 for both).

Conclusion

Zoledronic acid treatment in elderly patients with primary osteoporosis demonstrates significant efficacy by increasing bone density, improving bone metabolism, enhancing QoL, and exhibiting high safety.
Literature
Arceo-Mendoza RM, Camacho PM (2021) Osteoporosis: latest guidelines. Updates on osteoporosis, an issue of endocrinology and metabolism clinics of North America, E-BookUpdates on Osteoporosis, An Issue of Endocrinology and Metabolism Clinics of North America, E-Book: Updates on Osteoporosis, An Issue of Endocrinology and Metabolism Clinics of North America, E-BookUpdates on Osteoporosis, An Issue of Endocrinology and Metabolism Clinics of North America, E-Book, 50(2):167
Brown JP (2021) Long-term treatment of postmenopausal osteoporosis. Endocrinol Metab 36(3):544–552CrossRef
Chi P-J, Shih-Yuan H, Hsiao F-T, Liou H-H, Tsai J-P (2022) Serum osteocalcin concentration as an independent biomarker of osteoporosis in patients with chronic kidney disease. Clin Nephrol 98(1):1CrossRefPubMed
Choo YW, Mohd Tahir NA, Mohamed Said MS, Makmor Bakry M (2024) Health-related quality of life in osteoporosis: a systematic review of measurement properties of the QUALEFFO-41. Osteoporos Int 35(5):745–757CrossRefPubMed
Ciosek Ż, Kot K, Kosik-Bogacka D, Łanocha-Arendarczyk N, Rotter I (2021) The effects of calcium, magnesium, phosphorus, fluoride, and lead on bone tissue. Biomolecules 11(4):506CrossRefPubMedPubMedCentral
Crack LE, Haider IT, Simonian N, Barroso J, Gabel L, Schnitzer TJ, Edwards WB (2023) Zoledronic acid after spinal cord injury mitigates losses in proximal femoral strength independent of ambulation ability. Osteoporos Int 34(9):1637–1645CrossRefPubMed
Gillies BR, Ryan BA, Tonkin BA, Poulton IJ, Ma Y, Kirby BJ, Kovacs CS (2018) Absence of calcitriol causes increased lactational bone loss and lower Milk calcium but does not impair post-lactation bone recovery in Cyp27b1 null mice. J Bone Miner Res 33(1):16–26CrossRefPubMed
Herrera-Martínez Y, Contreras González MJ, Pedraza-Arévalo S, Guerrero Martínez MDC, Rodrigo Martínez Á, González Menchen A, Luque RM (2022) Calcitriol-mediated hypercalcemia, somatostatin receptors expression and 25-hydroxyvitamin D3–1α-hydroxylase in GIST tumors. Front Endocrinol 12:812385CrossRef
Hu Q, Wang Q, Liu F, Yao L, Zhang L, Chen G (2022) Combination of calcitriol and zoledronic acid on PINP and β-CTX in postoperative patients with diabetic osteoporosis: a randomized controlled trial. Dis Mark 2022(1):6053410
Jing W, Dai Y, Zhu J, Deng S (2022) [Retracted] Clinical efficacy and safety evaluation of calcitriol combined with bisphosphonates in the therapy of postmenopausal osteoporosis: based on a retrospective cohort study. BioMed Res Int 2022(1):2711938CrossRefPubMedPubMedCentral
Kashii M, Kamatani T, Nagayama Y, Miyama A, Tsuboi H, Ebina K (2023) Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis. Osteoporos Int 34(3):563–572CrossRefPubMed
Lee Y-K, Kim H-J, Park JW, Won S, Hwang J-S, Ha Y-C, Koo K-H (2019) Transcultural adaptation and psychometric properties of the Korean version of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO-41). Arch Osteoporos 14:1–7CrossRef
Li R, Liu H, Dilger JP, Lin J (2018) Effect of propofol on breast cancer cell, the immune system, and patient outcome. BMC Anesthesiol 18:1–8CrossRef
Liu H, Xiong Y, Zhu X, Gao H, Yin S, Wang J, Wang P (2017) Icariin improves osteoporosis, inhibits the expression of PPARγ, C/EBPα, FABP4 mRNA, N1ICD and jagged1 proteins, and increases Notch2 mRNA in ovariectomized rats. Exp Therap Med 13(4):1360–1368CrossRef
Liu C, Kuang X, Li K, Guo X, Deng Q, Li D (2020) Effects of combined calcium and vitamin D supplementation on osteoporosis in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Food Funct 11(12):10817–10827CrossRefPubMed
Lu L, Lu L, Zhang J, Li J (2020) Potential risks of rare serious adverse effects related to long-term use of bisphosphonates: an overview of systematic reviews. J Clin Pharm Therap 45(1):45–51CrossRef
Miller PD, Adachi JD, Albergaria BH, Cheung AM, Chines AA, Gielen E, Reid IR (2020) Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Res 37(8):1437–1445CrossRef
Møller AM, Delaisse JM, Olesen JB, Bechmann T, Madsen JS, Søe K (2020) Zoledronic acid is not equally potent on osteoclasts generated from different individuals. J Bone Miner Res plus 4(11):e10412
Ni H, Zhang S, Niu X, Dai S (2022) Meta-analysis of effects of nutritional intervention combined with calcium carbonate D3 tablets on bone mineral density, bone metabolism, and curative effect in patients with osteoporosis. Contrast Media Mol Imaging 2022(1):3670007CrossRefPubMedPubMedCentral
Qaseem A, Hicks LA, Etxeandia-Ikobaltzeta I, Shamliyan T, Cooney TG, Physicians CGC (2023) Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians. Ann Internal Med 176(2):224–238CrossRef
Riancho JA (2023) Diagnostic approach to patients with low serum alkaline phosphatase. Calcif Tissue Int 112(3):289–296CrossRefPubMed
Rinonapoli G, Ruggiero C, Meccariello L, Bisaccia M, Ceccarini P, Caraffa A (2021) Osteoporosis in men: a review of an underestimated bone condition. Int J Mol Sci 22(4):2105CrossRefPubMedPubMedCentral
Rouco H, García-García P, Briffault E, Diaz-Rodriguez P (2023) Modulating osteoclasts with nanoparticles: a path for osteoporosis management? Wiley Interdiscip Rev: Nanomed Nanobiotechnol 15(4):e1885PubMed
Tanner L, Bergwik J, Single AB, Bhongir RK, Erjefält JS, Egesten A (2022) Zoledronic acid targeting of the mevalonate pathway causes reduced cell recruitment and attenuates pulmonary fibrosis. Front Pharmacol 13:899469CrossRefPubMedPubMedCentral
Vasikaran SD, Miura M, Pikner R, Bhattoa HP, Cavalier E, IOF-IFCC Joint Committee on Bone Metabolism (C-BM) (2023) Practical considerations for the clinical application of bone turnover markers in osteoporosis. Calcif Tissue Int 112:148–157CrossRefPubMed
Widiyanto T, Hidayat R, Wibowo RSAK, Shatri H (2022) Correlation between anti-mutated citrullinated vimentin and bone turnover markers (CTX-1 and P1NP) in patients with rheumatoid arthritis in remission and low-disease activity. Reumatologia/rheumatology 60(1):252–257CrossRefPubMed
Zafar S, Cullinan MP, Drummond BK, Seymour GJ, Coates DE (2020) Effects of zoledronic acid and geranylgeraniol on angiogenic gene expression in primary human osteoclasts. J Oral Sci 62(1):79–83CrossRefPubMed
Zhang Q, Yin L, Lai Q, Zhao Y, Peng H (2023) Advances in the pathogenesis and therapeutic strategies of angioimmunoblastic T-cell lymphoma. Clin Exp Med 23(8):4219–4235CrossRefPubMed
Metadata
Title
Therapeutic efficacy of zoledronic acid combined with calcium and calcitriol in the treatment of senile osteoporosis in elderly patients
Authors
Yi Zhang
Yuan Tian
Xiaojun Chen
Publication date
05-03-2025
Publisher
Springer International Publishing
Published in
Inflammopharmacology
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI
https://doi.org/10.1007/s10787-025-01683-4